Imidazoline binding sites in Huntington's and Parkinson's disease putamen.
Binding of [3H]2-(2-benzofuranyl)-2-imidazoline ([3H]BFI) to the imidazoline I2 receptor was determined in putamen taken post mortem from patients with two extrapyramidal motor disorders, Parkinson's and Huntington's diseases, and age-matched control subjects. No deficit of binding was apparent in Parkinson's disease, indicating that the receptors are not present on nigrostriatal terminals. A significant loss (by 56%) in imidazoline I2 receptor binding was observed in Huntington's disease, consistent with the receptors being sited on degenerating neurons.
Reynolds
G P
GP
Department of Biomedical Science, University of Sheffield, UK.
Boulton
R M
RM
Pearson
S J
SJ
Hudson
A L
AL
Nutt
D J
DJ
D000317:Adrenergic alpha-Antagonists / Q000493:pharmacokinetics; D001923:Brain Chemistry / Q000502:physiology*; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism*; D019329:Idazoxan / Q000493:pharmacokinetics; D054755:Imidazoline Receptors; D010300:Parkinson Disease / Q000378:metabolism*; D011699:Putamen / Q000187:drug effects / Q000378:metabolism; D011955:Receptors, Drug / Q000187:drug effects / Q000378:metabolism*
D000317:Adrenergic alpha-Antagonists; D054755:Imidazoline Receptors; D011955:Receptors, Drug; D019329:Idazoxan